Comparative Pharmacology
Head-to-head clinical analysis: FEMCON FE versus LEVORA 0 15 30 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMCON FE versus LEVORA 0 15 30 21.
FEMCON FE vs LEVORA 0.15/30-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone and ethinyl estradiol. Inhibits ovulation via suppression of gonadotropins (FSH, LH); increases cervical mucus viscosity, impairing sperm penetration; alters endometrial receptivity.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
One tablet (norethindrone 0.5 mg + ethinyl estradiol 35 mcg) orally once daily for 28 days.
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
None Documented
None Documented
The terminal elimination half-life of ethinyl estradiol is 13-18 hours; for norethindrone, it is 7-12 hours. Both allow once-daily dosing for contraceptive efficacy.
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Renal excretion accounts for approximately 40-60% of the dose as metabolites; fecal excretion is about 20-30% via bile. Unchanged drug excretion is minimal.
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive